399 related articles for article (PubMed ID: 19375689)
1. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
4. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
5. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
6. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
8. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
10. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
13. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
16. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE
Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
[TBL] [Abstract][Full Text] [Related]
17. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
